Research ArticleBasic Science Investigations
Does Imaging αvβ3 Integrin Expression with PET Detect Changes in Angiogenesis During Bevacizumab Therapy?
Svetlana N. Rylova, Enikö Barnucz, Melpomeni Fani, Friederike Braun, Martin Werner, Silke Lassmann, Helmut R. Maecke and Wolfgang A. Weber
Journal of Nuclear Medicine November 2014, 55 (11) 1878-1884; DOI: https://doi.org/10.2967/jnumed.114.137570
Svetlana N. Rylova
1German Cancer Consortium (DKTK), Heidelberg, Germany
2Department of Nuclear Medicine, University Medical Center, Freiburg, Germany
3German Cancer Research Center (DKFZ), Heidelberg, Germany
Enikö Barnucz
4Department of Pathology, University Medical Center, Freiburg, Germany
Melpomeni Fani
2Department of Nuclear Medicine, University Medical Center, Freiburg, Germany
Friederike Braun
2Department of Nuclear Medicine, University Medical Center, Freiburg, Germany
Martin Werner
1German Cancer Consortium (DKTK), Heidelberg, Germany
3German Cancer Research Center (DKFZ), Heidelberg, Germany
4Department of Pathology, University Medical Center, Freiburg, Germany
Silke Lassmann
1German Cancer Consortium (DKTK), Heidelberg, Germany
3German Cancer Research Center (DKFZ), Heidelberg, Germany
4Department of Pathology, University Medical Center, Freiburg, Germany
5BIOSS Center for Biological Signaling Studies, Freiburg, Germany; and
Helmut R. Maecke
2Department of Nuclear Medicine, University Medical Center, Freiburg, Germany
Wolfgang A. Weber
6Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 55, Issue 11
November 1, 2014
Does Imaging αvβ3 Integrin Expression with PET Detect Changes in Angiogenesis During Bevacizumab Therapy?
Svetlana N. Rylova, Enikö Barnucz, Melpomeni Fani, Friederike Braun, Martin Werner, Silke Lassmann, Helmut R. Maecke, Wolfgang A. Weber
Journal of Nuclear Medicine Nov 2014, 55 (11) 1878-1884; DOI: 10.2967/jnumed.114.137570
Does Imaging αvβ3 Integrin Expression with PET Detect Changes in Angiogenesis During Bevacizumab Therapy?
Svetlana N. Rylova, Enikö Barnucz, Melpomeni Fani, Friederike Braun, Martin Werner, Silke Lassmann, Helmut R. Maecke, Wolfgang A. Weber
Journal of Nuclear Medicine Nov 2014, 55 (11) 1878-1884; DOI: 10.2967/jnumed.114.137570
Jump to section
Related Articles
Cited By...
- 68Ga-DOTA-E[c(RGDfK)]2 PET Imaging of SHARPIN-Regulated Integrin Activity in Mice
- Response Assessment of 68Ga-DOTA-E-[c(RGDfK)]2 PET/CT in Lung Adenocarcinoma Patients Treated with Nintedanib Plus Docetaxel
- Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers
- RGD PET: From Lesion Detection to Therapy Response Monitoring